Precision Neuroscience Raises $41 Million To Build And Scale The Next Generation Of Treatments For Neurological Illnesses
Precision Neuroscience Raises $41 Million To Build And Scale The Next Generation Of Treatments For Neurological Illnesses
01/25/23, 1:03 PM
Location
manhattan beachMoney raised
$41 million
Precision Neuroscience Corporation, the only brain–computer interface (BCI) company developing implants that are designed to be high-resolution, minimally invasive, and reversible, today announced a $41 million Series B funding round led by Forepont Capital Partners. Mubadala Capital, Draper Associates, Alumni Ventures, and re.Mind Capital also participated in the round, alongside existing investors Steadview Capital and B Capital Group. The new financing enables Precision to continue hiring top talent, while powering further product development and paving the road to FDA regulatory review, expected in the coming months. The latest investment brings the company’s total funding to $53 million in under two years.
Company Info
Location
manhattan beach, california, united states
Additional Info
Precision Neuroscience’s goal is to provide breakthrough treatments for the one billion people worldwide suffering from neurological illnesses. We are building the only brain–computer interface that is designed to be minimally invasive, safely removable, and capable of processing large amounts of data. To learn more about how Precision is connecting human intelligence and artificial intelligence, visit www.precisionneuro.io.